Acute Pulmonary Embolism, Part 2: Treatment, Disposition, and Preventing Collapse

Applying the A–E classification to anticoagulation, reperfusion, monitoring, and follow-up in the emergency department

Pulmonary embolism does not kill by clot burden.

It kills by right ventricular failure.

The role of the emergency physician is not simply to diagnose PE—but to identify which patient will deteriorate, which patient needs reperfusion, and which patient can safely go home.

The 2026 AHA/ACC/ACEP classification (A–E) provides a physiology-based roadmap for treatment escalation, monitoring, and disposition.

This is where classification becomes action.

Step 1: Immediate ED Stabilization

COR 1, LOE B-NR

Initial management priorities in suspected or confirmed PE:

• Oxygenation
• Circulatory support
• RV perfusion preservation
• Prevention of hemodynamic collapse

Key immediate assessments:

• Blood pressure
• Oxygen requirement
• Lactate
• Mental status
• RV function

Patients in Category D or E require immediate resuscitation.

Oxygen and Respiratory Support

COR 1, LOE C-LD

Indicated in hypoxemic patients.

Target:

SpO₂ ≥ 90%-94%

Preferred escalation:

1. Nasal cannula

2. High-flow nasal oxygen

3. Non-invasive ventilation

Avoid unnecessary intubation.

Positive pressure ventilation reduces venous return and worsens RV failure.¹

If intubation unavoidable:

• Use hemodynamically stable induction agents
• Initiate vasopressors first

—> Physiologically difficult airway modification, give RV supporting ionotropes.

Circulatory Support

COR 1, LOE B-NR

Hypotension reflects RV failure and impaired cardiac output.

First-line vasopressor:

Norepinephrine

Benefits:

• Improves coronary perfusion
• Improves RV contractility
• Improves systemic vascular resistance¹

Avoid aggressive fluid boluses.

Excess fluid worsens RV dilation and reduces LV filling.

Step 2: Anticoagulation — The Foundation of Treatment

Anticoagulation prevents clot propagation and allows endogenous fibrinolysis.

COR 1, LOE A

Anticoagulation is recommended in all patients with confirmed PE unless contraindicated.¹

Choice of Anticoagulant

DOACs preferred in stable patients

COR 1, LOE A

Preferred agents:

• Apixaban
• Rivaroxaban

Advantages:

• Lower bleeding risk
• Rapid onset
• No monitoring required
• Suitable for outpatient treatment¹

LMWH preferred when inpatient management required

COR 1, LOE B-R

Preferred in:

• Hospitalized patients
• Cancer-associated thrombosis
• Moderate-risk PE¹

Advantages:

• Predictable anticoagulation
• Lower HIT risk

UFH preferred in unstable patients

COR 1, LOE B-NR

Indications:

• Category C3
• Category D
• Category E
• Planned thrombolysis or thrombectomy¹

Reason:

Rapid reversibility.

Step 3: Reperfusion Therapy

Indicated in RV failure and shock

Reperfusion reduces RV afterload and restores circulation.

Systemic Thrombolysis

COR 1, LOE B-R

Indicated in:

Category E1 — cardiogenic shock
Category E2 — cardiac arrest¹

Reduces mortality and improves hemodynamics.

Consider thrombolysis in Category D

COR 2a, LOE B-NR

Indicated if evidence of:

• Normotensive shock
• Elevated lactate
• Progressive hypoxia
• RV dysfunction¹

These patients are at high risk of deterioration.

Not recommended routinely in Category C

COR 3, LOE B-R

Routine thrombolysis in stable patients increases bleeding risk without mortality benefit.

Alteplase (tPA) Dose for Acute Pulmonary Embolism

Standard dose for high-risk PE (massive PE with shock)

Dose: 100 mg IV over 2 hours

Regimen:

• 100 mg alteplase IV infusion over 120 minutes

• No bolus required (standard regimen)

This is the FDA-approved and guideline-recommended dose.

Alternative accelerated regimen (commonly used in ED / ICU)

Dose: 0.6 mg/kg IV over 15 minutes (max 50 mg)

Used when:

• Rapid hemodynamic collapse

• Need for faster reperfusion

• Peri-arrest or severe shock

Evidence shows similar efficacy with potentially lower bleeding risk.

Alteplase Dose During Cardiac Arrest due to PE

When PE is suspected or confirmed cause of arrest:

Recommended regimen (AHA cardiac arrest guidance)

50 mg IV bolus over 2–5 minutes

Then:

• Continue CPR for at least 15–30 minutes

• If no ROSC, may repeat another 50 mg bolus after 15–30 minutes

Maximum total dose: 100 mg

Most commonly used cardiac arrest protocol in emergency medicine

Option 1 (most widely used):

• Alteplase 50 mg IV push

• Continue CPR 15–30 min

• Repeat 50 mg if needed

Option 2 (alternative):

• Alteplase 100 mg IV bolus over 10 minutes

Used less commonly due to bleeding risk.

---

Catheter-Directed Therapy

COR 2a, LOE B-NR

Indicated when:

• Thrombolysis contraindicated
• Failed thrombolysis
• Progressive deterioration¹

Advantages:

• Lower bleeding risk
• Targeted therapy

---

Mechanical Thrombectomy

COR 2a, LOE B-NR

Indications:

• Category D or E
• Contraindication to thrombolysis
• Failed thrombolysis¹

Improves hemodynamics rapidly.

Increasingly used in modern PE management.

---

ECMO

COR 2a, LOE C-LD

Indicated in refractory shock or cardiac arrest.

Provides circulatory support until reperfusion effective.

---

Step 4: Treatment and Disposition by A–E Group

This is the most important ED decision.

Category A — Incidental PE

Mortality risk: <1%

Treatment:

Anticoagulation or observation depending on risk factors¹

Disposition:

Discharge with outpatient follow-up

Category B — Symptomatic, Low Risk

Mortality risk: ~1%

Treatment:

DOAC preferred¹

Disposition:

Outpatient management recommended

Criteria:

• Stable vitals
• No hypoxia
• Reliable follow-up¹

Category C1 — Intermediate Risk, No RV Injury

Mortality risk: 3–5%

Treatment:

Anticoagulation¹

Disposition:

Hospital admission, telemetry

Category C2 — RV Injury or Biomarker Elevation

Mortality risk: 5–15%

Treatment:

Anticoagulation

Disposition:

Hospital admission with monitoring¹

Category C3 — RV Injury + Biomarker Elevation

Mortality risk: 15–30%

Treatment:

UFH preferred
Consider reperfusion if deterioration¹

Disposition:

Step-down or ICU

PERT consultation recommended.

Category D — Normotensive Shock

Mortality risk: 20–40%

Treatment:

UFH
Consider thrombolysis or thrombectomy¹

Disposition:

ICU

Immediate specialist consultation required.

Category E — Cardiogenic Shock or Arrest

Mortality risk: >40%

Treatment:

Immediate reperfusion therapy¹

Options:

• Thrombolysis
• Thrombectomy
• ECMO

Disposition:

ICU

Medical emergency.

Step 5: Monitoring

COR 1, LOE B-NR

Monitor for deterioration:

• Blood pressure
• Oxygen requirement
• Heart rate
• Lactate
• Mental status¹

Serial reassessment essential.

Patients may deteriorate rapidly.

Step 6: Complications and Sequelae

Acute complications

Right ventricular failure
Cardiogenic shock
Cardiac arrest

Primary causes of death.

Chronic thromboembolic pulmonary hypertension (CTEPH)

Occurs in 2–4% of patients.¹

Caused by persistent pulmonary vascular obstruction.

Symptoms:

• Progressive dyspnea
• Exercise intolerance

Post-PE syndrome

Occurs in up to 50% of patients.¹

Symptoms:

• Dyspnea
• Reduced exercise tolerance
• Functional impairment

---

Step 7: Duration of Anticoagulation

COR 1, LOE A

Minimum duration:

3 months¹

Extended anticoagulation recommended if:

• Unprovoked PE
• Persistent risk factors¹

I break down emergency medicine physiology visually and practically.
If you’re an emergency physician, resident, or acute care clinician, you’ll find additional diagrams, algorithms, and case-based insights here:

→ Follow on Instagram: @humans.of.em

This is where most of my visual teaching lives.

Reference

1. American College of Cardiology/American Heart Association Joint Committee. 2026 AHA/ACC guideline for the diagnosis and management of acute pulmonary embolism. J Am Coll Cardiol. 2026.